Results 81 to 90 of about 1,768,893 (247)

Development of Live-Attenuated Influenza Vaccines against Outbreaks of H5N1 Influenza

Viruses, 2012
Several global outbreaks of highly pathogenic avian influenza (HPAI) H5N1 virus have increased the urgency of developing effective and safe vaccines against H5N1.
Yinglei Yi, Dan Zheng, Ze Chen
doaj   +1 more source

Influenza Viruses with Rearranged Genomes as Live-Attenuated Vaccines [PDF]

Journal of Virology, 2013
ABSTRACT H5N1 and H9N2 avian influenza virus subtypes top the World Health Organization's list for the greatest pandemic potential. Inactivated H5N1 vaccines induce limited immune responses and, in the case of live-attenuated influenza virus vaccines (LAIV), there are safety concerns regarding the possibility of reassortment ...
Lindomar, Pena, Troy, Sutton, Ashok, Chockalingam, Sachin, Kumar, Matthew, Angel, Hongxia, Shao, Hongjun, Chen, Weizhong, Li, Daniel R, Perez   +8 more
openaire   +2 more sources

Improved adjuvanting of seasonal influenza vaccines: Pre-clinical studies of MVA-NP+M1 co-administration with inactivated influenza vaccine. [PDF]

, 2013
Licensed seasonal influenza vaccines induce antibody responses against influenza hemagglutinin that are limited in their ability to protect against different strains of influenza.
Gilbert, SC, Temperton, Nigel J., Charleston, Bryan, Molesti, E, Sarah C. Gilbert, Butter, Colin, Massimiliano Baratelli, Lambe, Teresa, Boyd, A, Mullarkey, CE, Charleston, B, Caitlin E. Mullarkey, Eleonora Molesti, Gilbert, Sarah, van Laarhoven, Arjan, Veronica Carr, B, van Laarhoven, A, Eric A. Lefevre, Molesti, Eleonora, Amy Boyd, Colin Butter, Mullarkey, Caitlin E, Gilbert, Sarah C, Lefevre, EA, B. Veronica Carr, Arjan van Laarhoven, Nigel J. Temperton, Lambe, T, Baratelli, M, Carr, B Veronica, Baratelli, Massimiliano, Lefevre, Eric A, Boyd, Amy, Temperton, NJ, Butter, C, Teresa Lambe, Bryan Charleston   +36 more
core   +1 more source

Development of a live attenuated vaccine candidate against herpesviral hematopoietic necrosis of goldfish

, 2022
Herpesviral hematopoietic necrosis causes huge economic loss in goldfish Carassius auratus and gibel carp C. auratus gibelio farming. To develop a live attenuated vaccine as a preventive measure against the disease, the causative virus cyprinid ...
Shibata, Tomoya, Sano, Motohiko, Saito, Hiroaki, Kato, Goshi, 加藤, 豪司, Okamura, Takumi, 佐野, 元彦, サノ, モトヒコ, 齊藤, 宏明, サイトウ, ヒロアキ, カトウ, ゴウシ   +10 more
core   +1 more source

Intravenous Lipopolysaccharide Challenge in Healthy Participants Reveals Pharmacodynamic Markers in Blood and Bone Marrow for Early‐Phase Oncology Drug Development

Clinical Pharmacology &Therapeutics, EarlyView.
Demonstrating pharmacological effects in early‐phase oncology clinical trials remains challenging, largely due to the lack of robust pharmacodynamic markers. Lipopolysaccharide (LPS) is used as an immune challenge agent in healthy participants to study drugs for autoimmune conditions.
Igor Radanović, Ingrid Tomljanović, Wieke H. Grievink, Diana R. Pereira, Michelle Osse, Peter van Balen, Maria J. Juachon, Marieke L. de Kam, Lisa Pagan, Manon A.A. Jansen, Matthijs Moerland, Jacobus J. Bosch   +11 more
wiley   +1 more source

Comparison of efficacy, safety, immune response of dNS1 LAIV and cold-adapted LAIV in a mouse model

npj Vaccines
Influenza remains a significant global public health concern. Live-attenuated influenza vaccines (LAIVs) are recognized as effective interventions for influenza prevention.
Xijing Wang, Xu Zhang, Congjie Chen, Heming Chen, Yaode Chen, Ruotong Wu, Xiangjie Chen, Zhen Lu, Ningshao Xia, Junyu Chen, Yixin Chen   +10 more
doaj   +1 more source

Interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1

Scientific Reports, 2021
The influenza A non-structural protein 1 (NS1) is known for its ability to hinder the synthesis of type I interferon (IFN) during viral infection. Influenza viruses lacking NS1 (ΔNS1) are under clinical development as live attenuated human influenza ...
Raveen Rathnasinghe, Mirella Salvatore, Hongyong Zheng, Sonia Jangra, Thomas Kehrer, Ignacio Mena, Michael Schotsaert, Thomas Muster, Peter Palese, Adolfo García-Sastre   +9 more
doaj   +1 more source

Viral Dynamic Model‐Informed Dose Selection of Mosnodenvir Prophylaxis against DENV‐3 in a Controlled Human Infection Model

Clinical Pharmacology &Therapeutics, EarlyView.
Dengue virus (DENV) infection is a significant global health threat. Mosnodenvir (JNJ‐64281802) is a pan‐serotype small molecule antiviral blocking DENV replication. A Phase IIa study (NCT05048875) evaluated the antiviral activity, safety, and pharmacokinetics of mosnodenvir as prophylaxis against DENV‐3 in a controlled human infection model (CHIM).
Nele Goeyvaerts, Xavier Woot de Trixhe, Martine Neyens, Thomas N. Kakuda, Liesbeth Van Wesenbeeck, Annemie Buelens, Freya Rasschaert, Anna Durbin, Oliver Ackaert   +8 more
wiley   +1 more source

The applications of live attenuated influenza a virus with modified NS1 gene

Molecular Therapy: Nucleic Acids
Currently, the most effective strategy to prevent influenza is vaccination. While the traditional inactivated influenza vaccine demonstrates favorable safety and effectiveness, live attenuated influenza vaccine (LAIV) offers unique advantages. It has the
Hongbo Zhang, Lei Wang, Youcai An, Ze Chen   +3 more
doaj   +1 more source

Immune responses after live attenuated influenza vaccination [PDF]

Human Vaccines & Immunotherapeutics, 2018
Since 2003 (US) and 2012 (Europe) the live attenuated influenza vaccine (LAIV) has been used as an alternative to the traditional inactivated influenza vaccines (IIV). The immune responses elicted by LAIV mimic natural infection and have been found to provide broader clinical protection in children compared to the IIVs.
Mohn, Kristin G. -I.; Smith, Ingrid; Sjursen, Haakon; Cox, Rebecca Jane   +4 more
openaire   +3 more sources